Azenta (AZTA) Life Sciences Higher After 4Q Earnings
b"Azenta (AZTA) is a provider of life sciences worldwide, enabling therapies to market faster. George Tsilis discusses AZTA as its trading higher after better-than-expected 4Q earnings. He talks about how AZTA announced a $1.5B share-repurchase program. He notes that the company's 4Q revenue came in at $138.00M versus an estimated $133.72M. He then goes over how AZTA works in areas such as drug development, clinical research, and advanced cell therapies. Tune in to find out more about the stock market today."